A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer

NCT00144053 Phase 3 COMPLETED

To evaluate whether two weekly concurrent chemoradiotherapy regimens offer any advantage over concurrent chemoradiotherapy regimens with Cisplatin, Vindesine, Mitomycin for unresectable stage III NSCLC.

Details

Lead sponsor	West Japan Thoracic Oncology Group
Phase	Phase 3
Status	COMPLETED
Enrolment	450
Start date	2001-04

Conditions

• Lung Cancer

Interventions

• Cisplatin+Vindesine+MMC/ concurrent radiation
• Irinotecan+Carboplatin/concurrent radiation
• Paclitaxel+Carboplatin/concurrent radiation

Primary outcomes

• Survival